TherapeuticsMD swings to Q1 net income as license revenue rises

TherapeuticsMD

12/05/2026 21:13

Overview

US pharmaceutical royalty company's Q1 license revenue rose yr/yr, driven by Mayne License Agreement

Company swung to net income from continuing operations after loss in prior-year quarter

TherapeuticsMD continues to evaluate strategic alternatives, including possible sale or merger

Outlook

Company continues to evaluate strategic alternatives, including possible merger, acquisition or asset sale

Result Drivers

LICENSE REVENUE GROWTH - Co said Q1 license revenue increase was mainly due to higher sales of products under the Mayne License Agreement

LOWER OPERATING EXPENSES - Co attributed reduced operating expenses to absence of prior-year write-off, and lower professional fees and share-based compensation

Company press release: ID:nBw80SKNna

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income from Cont Ops
$103,000
Q1 Operating Expenses
$1.45 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)